Journal of Thoracic Disease 2022 August [Link] Olivia Lauk, Thomas Neuer, Bianca Battilana, Ilhan Inci, Katarzyna Furrer, Walter Weder, Masaki Hashimoto, Isabelle Opitz Abstract Background: Malignant pleural mesothelioma (MPM) is associated with high rates of local recurrence (LR) up to 75%. Second line treatment should be applied tailored to relapse pattern. We aimed to establish…

Read More

Journal of Thoracic Oncology 2022 September 5 [Link] Michael Offin, Dilanka De Silva, Jennifer L Sauter, Jacklynn V Egger, Ellen Yorke, Prasad S Adusumilli, Andreas Rimner, Valerie W Rusch, Marjorie G Zauderer Abstract Background: Primary pericardial mesothelioma (PPM) has no accepted standard of care treatment options with management and outcomes often extrapolated from diffuse pleural…

Read More

Journal of Chest Surgery 2022 September 7 [Link] Muhammet Sayan, Aynur Bas, Merve Satir Turk, Dilvin Ozkan, Ali Celik, İsmail Cuneyt Kurul, Abdullah Irfan Tastepe Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive pleural malignancy, and despite all multimodal treatment modalities, the 5-year overall survival rate of patients with MPM is less than 20%.…

Read More

Updates in Surgery 2022 September 3 [Link] Dimitrios E Magouliotis, Prokopis-Andreas Zotos, Arian Arjomandi Rad, Despoina Koukousaki, Vasiliki Vasilaki, Ioustini Portesi, Kyriakos Spiliopoulos, Thanos Athanasiou Abstract Objective: We reviewed the available literature on patients with MPM undergoing either extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D). Methods: Original research studies that evaluated long-term outcomes of P/D versus…

Read More

Pilot & Feasibility Studies 2022 September 3 [Link] Anna C Bibby, Natalie Zahan-Evans, Emma Keenan, Charles Comins, John E Harvey, Helen Day, Najib M Rahman, Janet E Fallon, Rachael Gooberman-Hill, Nick A Maskell Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive thoracic malignancy with a poor prognosis. Systemic immunotherapy is an effective frontline treatment…

Read More

Thoracic Cancer 2022 September 2 [Link] Francesco Falanga, Pietro Rinaldi, Cristiano Primiceri, Chandra Bortolotto, Olga Oneta, Francesco Agustoni, Patrizia Morbini, Laura Saracino, Dimitrios Eleftheriou, Federico Sottotetti, Giulia Maria Stella Abstract Surgery is part of a multimodal therapeutic approach to malignant pleural mesothelioma (MPM) although its real beneficial effect is still controversial. The optimal precise sequence…

Read More

Molecular Oncology 2022 August 28 [Link] Hoa-Le Mai, Sophie Deshayes, Thi-Van-Ha Nguyen, Virginie Dehame, Anne-Laure Chéné, Sophie Brouard, Christophe Blanquart Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer mainly related to asbestos exposure. Despite recent therapeutic advances, notably immunotherapies, the benefit remains limited and restricted to a small percentage of patients. Thus, a better…

Read More

Cancer Medicine 2022 August 28 [Link] Yue Jiang, Chengda Zhang, Yang Chen, Shiyu Zhao, Yipeng He, Jun He Abstract Background: Malignant pleural mesothelioma (MPM) is a rare and highly malignant thoracic tumor. Although alternative splicing (AS) is associated with tumor prognosis, the prognostic significance of AS in MPM is unknown. Methods: Transcriptomic data, clinical information,…

Read More

Radiation Oncology 2022 August 26 [Link] Davide Franceschini, Luca Cozzi, Antonella Fogliata, Beatrice Marini, Luciana Di Cristina, Luca Dominici, Ruggero Spoto, Ciro Franzese, Pierina Navarria, Tiziana Comito, Giacomo Reggiori, Stefano Tomatis, Marta Scorsetti Abstract Background: To investigate the performance of a narrow-scope knowledge-based RapidPlan (RP) model for optimisation of intensity-modulated proton therapy (IMPT) and volumetric…

Read More

Clinical Cancer Research 2022 August 22 [Link] Amanda M Nash, Samira Aghlara-Fotovat, Bertha Castillio, Andrea Hernandez, Aarthi Pugazenthi, Hyun-Sung Lee, Hee-Jin Jang, Annie Nguyen, Alexander Lu, Bryan M Burt, Ravi K Ghanta, Omid Veiseh Abstract Purpose: Interleukin-2 (IL-2) immunotherapy has the potential to elicit immune-mediated tumor lysis via activation of effector immune cells, but clinical…

Read More